ProGene Biomedical, Inc. Release: Ampersand Ventures Invests In IBT Reference Laboratory Funding To Expand IBT's Pharmaceutical Services Business
10/19/2005 5:12:20 PM
ProGene Biomedical, Inc. (d/b/a IBT Reference Laboratory), a national clinical reference laboratory specializing in clinical immunology and allergy testing, today announced that it has received $5 million in equity financing from Ampersand Ventures. The funding will be used to expand IBT's pharmaceutical services business supporting preclinical and clinical R&D at major pharmaceutical and biotechnology companies, as well as add to its menu of specialized diagnostic tests offered to hospitals, physician practices and major clinical reference laboratories.
comments powered by